Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira Q1 revenue rises 5% to $177.4 million; 2026 guidance reiterated

Mixed Impact 3 of 5 earnings Written later

Pacira BioSciences reported first-quarter 2026 total revenue of $177.4 million, up 5% from $168.9 million a year earlier, led by EXPAREL volume growth of 7%. Profit fell, with GAAP net income of $2.9 million ($0.07 per share) versus $4.8 million ($0.10 per share) and non-GAAP net income of $24.5 million ($0.60 per share) versus $30.0 million. The company reiterated its full-year 2026 guidance, including total revenue of $745 million to $770 million.

Key points

  • Total revenue $177.4 million in Q1 2026, up from $168.9 million in Q1 2025; EXPAREL net product sales $143.3 million, up 5%
  • GAAP net income $2.9 million ($0.07 per share) vs. $4.8 million ($0.10) a year earlier; adjusted EBITDA $40.2 million vs. $44.1 million
  • Repurchased 2.2 million shares for $50.0 million in Q1; $100.0 million remains on the authorization, which expires December 31, 2026
  • 2026 guidance reiterated: total revenue $745 million to $770 million; EXPAREL net product sales $600 million to $620 million

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECApr 30, 2026, 4:03 PM ET
Accession number0001628280-26-028854

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.